Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 12, 2013 - Issue 3
Submit an article Journal homepage
724
Views
14
CrossRef citations to date
0
Altmetric
Reviews

Oxycodone combined with opioid receptor antagonists: efficacy and safety

Mellar DavisTaussig Cancer Institute, Cleveland Clinic, Harry R. Horvitz Center for Palliative Medicine, Department of Solid Tumor Oncology, 9500 Euclid Ave, Cleveland, OH 44195, [email protected]
, MD FCCP FAAHPM,
Harold W GoforthTaussig Cancer Institute, Cleveland Clinic, Harry R. Horvitz Center for Palliative Medicine, Department of Solid Tumor Oncology, 9500 Euclid Ave, Cleveland, OH 44195, [email protected]
, MD FAPM &
Pam GamierTaussig Cancer Institute, Cleveland Clinic, Harry R. Horvitz Center for Palliative Medicine, Department of Solid Tumor Oncology, 9500 Euclid Ave, Cleveland, OH 44195, [email protected]
, RN BSN CHPN
Pages 389-402 | Published online: 28 Mar 2013

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Shilan Mozaffari, Shekoufeh Nikfar & Mohammad Abdollahi. (2018) Investigational opioid antagonists for treating opioid-induced bowel dysfunction. Expert Opinion on Investigational Drugs 27:3, pages 235-242.
Read now
Fabio Guerriero, Niccolo Maurizi, Matthew Francis, Carmelo Sgarlata, Giovanni Ricevuti, Mariangela Rondanelli, Simone Perna & Marco Rollone. (2015) Is oxycodone/naloxone effective and safe in managing chronic pain of a fragile elderly patient with multiple skin ulcers of the lower limbs? A case report. Clinical Interventions in Aging 10, pages 1283-1287.
Read now
Stefano de Biase, Giovanni Merlino, Simone Lorenzut, Mariarosaria Valente & Gian Luigi Gigli. (2014) Investigational approaches to therapies for restless legs syndrome. Expert Opinion on Investigational Drugs 23:6, pages 847-856.
Read now

Articles from other publishers (11)

Olabisi Lane, Vats Ambai, Arjun Bakshi & Sudheer Potru. (2023) Alcohol use disorder in the perioperative period: a summary and recommendations for anesthesiologists and pain physicians. Regional Anesthesia & Pain Medicine, pages rapm-2023-104354.
Crossref
Aibing Zhu, Fei Yao & Mingkun Shen. (2023) Oxycodone alleviates mifepristone‐stimulated human endometrial stromal cell injury by activating the Keap1/Nrf2/HO‐1 signaling pathway. Immunity, Inflammation and Disease 11:9.
Crossref
Zijian Li, Yue You, Noreen Griffin, Juan Feng & Fengping Shan. (2018) Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy. International Immunopharmacology 61, pages 178-184.
Crossref
Ronald S. Litman, Olivia H. Pagán & Theodore J. Cicero. (2018) Abuse-deterrent Opioid Formulations. Anesthesiology 128:5, pages 1015-1026.
Crossref
Joseph V. PergolizziJr.Jr., Jo Ann LeQuang, Garrett K. Berger & Robert B. Raffa. (2017) The Basic Pharmacology of Opioids Informs the Opioid Discourse about Misuse and Abuse: A Review. Pain and Therapy 6:1, pages 1-16.
Crossref
Sebastiano MercadanteGiampiero PorzioVittorio Gebbia. (2014) New Opioids. Journal of Clinical Oncology 32:16, pages 1671-1676.
Crossref
Anne Z. DePriest & Katie Miller. (2014) Oxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse Deterrence. Pain and Therapy 3:1, pages 1-15.
Crossref
Jarred Younger, Luke Parkitny & David McLain. (2014) The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology 33:4, pages 451-459.
Crossref
Howard S. Smith & Andras Laufer. (2014) Opioid induced nausea and vomiting. European Journal of Pharmacology 722, pages 67-78.
Crossref
Flannery Fielding, Tanya M Sanford & Mellar P Davis. (2013) Achieving effective control in cancer pain: a review of current guidelines. International Journal of Palliative Nursing 19:12, pages 584-591.
Crossref
Jingjuan Meng, Yiming Meng, Nicholas P. Plotnikoff, Gene Youkilis, Noreen Griffin & Fengping Shan. (2013) Low dose naltrexone (LDN) enhances maturation of bone marrow dendritic cells (BMDCs). International Immunopharmacology 17:4, pages 1084-1089.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.